Abstract
Background and Objectives
In the past, subacute thyroiditis causing thyrotoxicosis included both painful and painless subgroup, but it is representative for the painful subacute thyroiditis these days. So we evaluated the clinical and laboratory characteristics of subacute thyroiditis and compared with the painless (silent) thyroiditis, and identified predictive factors of permanent hypothyroidism and recurrence.
Materials and Methods
This was a retrospective case series study analyzing clinical data of 221 consecutive patients diagnosed between 2009 and 2015. Medical records were reviewed for diagnostic route, age distribution, laboratory data, clinical course and long-term follow up outcome.
Results
The mean age was 48 years; female v/s male ratio 3.4:1. Median disease duration was 110 days; mean peak free T4 level was 2.9 ng/dL. 56.7% of painless thyroiditis patients were diagnosed on health checkup or routine thyroid function test with symptoms not typically associated with thyrotoxicosis. Permanent hypothyroidism was not uncommon (11/221; 5.0%). Higher peak thyroid-stimulating hormone (TSH) was associated with permanent hypothyroidism in painless thyroiditis. Lower peak TSH was associated with recurrence rate in both subacute and painless thyroiditis. In painless thyroiditis, short duration of thyrotoxicosis phase was also associated with recurrence rate.
References
1. Volpe R. Subacute (de Quervain's) thyroiditis. Clin Endocrinol Metab. 1979; 8(1):81–95.
2. Walfish PG. Thyroiditis. Curr Ther Endocrinol Metab. 1997; 6:117–22.
3. Ross DS. Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol Metab Clin North Am. 1998; 27(1):169–85.
6. Slatosky J, Shipton B, Wahba H. Thyroiditis: differential diagnosis and management. Am Fam Physician. 2000; 61(4):1047–52. 54.
7. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003; 88(5):2100–5.
8. Tikkanen MJ, Lamberg BA. Hypothyroidism following subacute thyroiditis. Acta Endocrinol (Copenh). 1982; 101(3):348–53.
9. Lio S, Pontecorvi A, Caruso M, Monaco F, D'Armiento M. Transitory subclinical and permanent hypothyroidism in the course of subacute thyroiditis (de Quervain). Acta Endocrinol (Copenh). 1984; 106(1):67–70.
10. Mizukoshi T, Noguchi S, Murakami T, Futata T, Yamashita H. Evaluation of recurrence in 36 subacute thyroiditis patients managed with prednisolone. Intern Med. 2001; 40(4):292–5.
11. Kitchener MI, Chapman IM. Subacute thyroiditis: a review of 105 cases. Clin Nucl Med. 1989; 14(6):439–42.
12. Hwang SC, Jap TS, Ho LT, Ching KN. Subacute thyroiditis–61 cases review. Zhonghua Yi Xue Za Zhi (Taipei). 1989; 43(2):113–8.
13. Alfadda AA, Sallam RM, Elawad GE, Aldhukair H, Alyahya MM. Subacute thyroiditis: clinical presentation and long term outcome. Int J Endocrinol. 2014; 2014:794943.
14. Benbassat CA, Olchovsky D, Tsvetov G, Shimon I. Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest. 2007; 30(8):631–5.
15. Erdem N, Erdogan M, Ozbek M, Karadeniz M, Cetinkalp S, Ozgen AG, et al. Demographic and clinical features of patients with subacute thyroiditis: results of 169 patients from a single university center in Turkey. J Endocrinol Invest. 2007; 30(7):546–50.
16. Kitaoka H, Sakurada T, Fukazawa H, Suzuki M, Kaise N, Kaise K, et al. An epidemiological study of subacute thyroiditis in northern Japan. Nihon Naibunpi Gakkai Zasshi. 1985; 61(5):554–70.
17. Iitaka M, Momotani N, Ishii J, Ito K. Incidence of subacute thyroiditis recurrences after a prolonged latency: 24-year survey. J Clin Endocrinol Metab. 1996; 81(2):466–9.
18. Martino E, Buratti L, Bartalena L, Mariotti S, Cupini C, Aghini-Lombardi F, et al. High prevalence of subacute thyroiditis during summer season in Italy. J Endocrinol Invest. 1987; 10(3):321–3.
19. Saito S, Sakurada T, Yamamoto M, Yamaguchi T, Yoshida K. Subacute thyroiditis: observations on 98 cases for the last 14 years. Tohoku J Exp Med. 1974; 113(2):141–7.
20. Iitaka M, Momotani N, Hisaoka T, Noh JY, Ishikawa N, Ishii J, et al. TSH receptor antibody-associated thyroid dysfunction following subacute thyroiditis. Clin Endocrinol (Oxf). 1998; 48(4):445–53.
21. Iitaka M, Kakinuma S, Yamanaka K, Fujimaki S, Oosuga I, Wada S, et al. Induction of autoimmune hypothyroidism and subsequent hyperthyroidism by TSH receptor antibodies following subacute thyroiditis: a case report. Endocr J. 2001; 48(2):139–42.
22. Nakamura S, Saio Y, Suzuki E. Subacute thyroiditis with thyroid-stimulation blocking antibodies: a case report. Endocr J. 1996; 43(2):185–9.
23. Hnilica P, Nyulassy S. Plasma cells in aspirates of goitre and overt permanent hypothyroidism following subacute thyroiditis. Preliminary report. Endocrinol Exp. 1985; 19(4):221–6.
Table 1.
All patients (n=221) |
Subacute thyroiditis (n=64) |
Painless thyroiditis (n=157) |
p value | |
---|---|---|---|---|
Age (years) (median, range) | 48 (23–88) | 50.5 (26–76) | 47.0 (23–88) | 0.078§ |
Female gender (%) | 77 (171/221) | 88 (56/64) | 73 (115/157) | 0.032† |
ESR (mm/h) (mean±SD) | 36.5±33.2 | 59.2±37.0 | 27.0±26.7 | <0.001§ |
Anti-TPO antibody (%) | 21 (9/43) | 14 (2/14) | 24 (7/29) | 0.693‡ |
Anti-TSH receptor antibody (%) | 6 (8/133) | 3 (1/27) | 6 (7/106) | >0.999‡ |
Peak FT4 (ng/dL) (mean±SD) | 2.93±3.3 | 4.0±5.8 | 2.5±1.3 | 0.738§ |
Duration of thyrotoxicosis (days) | 52.9 | 39.5 | 59.1 | 0.038§ |
Peak TSH (mU/L) (median) | 22 | 21 | 22 | 0.057§ |
Overall duration (days) (median) | 110 | 120 | 106 | 0.800§ |
Permanent hypothyroid (%) | 5 (11/221) | 8 (5/64) | 4 (6/157) | 0.304‡ |
Recurrence (%) | 12 (28/221) | 9 (6/64) | 14 (22/157) | 0.994‡ |
Table 2.
Subacute patients (n=64) |
Permanent hypothyroidism in subacute thyroiditis (n=5) |
p value |
Painless thyroiditis (n=157) |
Permanent hypothyroidism in painless thyroiditis (n=6) |
p value | |
---|---|---|---|---|---|---|
Anti-TPO antibody (%) | 14 (2/14) | 0 (0/2) | >0.999† | 24 (7/29) | 66 (2/3) | 0.136† |
Anti-TSH receptor antibody (%) | 3 (1/27) | 0 (0/1) | >0.999† | 6 (7/106) | 33 (1/3) | 0.178† |
Peak TSH (mU/L) (median) | 21 | 35 | 0.127∗ | 22 | 53 | <0.001∗ |
Overall duration (days) (median) | 120 | 430 | <0.001∗ | 106 | 868 | <0.001∗ |
Table 3.
Subacute thyroiditis patients (n=64) |
Recurrence in subacute thyroiditis (n=6) (9%) |
p value |
Painless thyroiditis (n=157) |
Recurrence in painless thyroiditis (n=22) (14%) |
p value | |
---|---|---|---|---|---|---|
Peak TSH (mU/L) | 21 | 12.72 | 0.007∗ | 22 | 6.38 | 0.018∗ |
Peak FT4 (ng/dL) (mean±SD) | 4.0±5.8 | 2.5±1.3 | 0.991∗ | 2.5±1.3 | 2.9±1.3 | 0.086∗ |
Duration of thyrotoxicosis (days) (mean) | 39.5 | 56.3 | 0.325∗ | 59.1 | 48.6 | 0.001∗ |
Overall duration (days) (median) | 120 | 100 | 0.566∗ | 106 | 112 | <0.001∗ |
Table 4.
Postpartum thyroiditis (n=15) |
Non-postpartum painless thyroiditis (n=142) |
p value | |
---|---|---|---|
Age (years) (median, range) | 35 (32–41) | 49.5 (23–88) | <0.001§ |
Female gender (%) | 100 (15/15) | 70 (100/142) | 0.012† |
Anti-TPO antibody>60 (%) | 60 (3/5) | 17 (4/24) | 0.075† |
Anti-TSH receptor antibody>10 (%) | 15 (2/13) | 5 (5/93) | 0.187† |
Peak FT4 (ng/dL) (mean±SD) | 2.2±1.2 | 2.7±1.6 | 0.135§ |
Peak TSH (mU/L) | 36.87 | 19.93 | 0.071§ |
Liver function test abnormality (%) | 30 (3/10) | 17 (21/124) | 0.384† |
Hypothyroid phase (%) | 53 (8/15) | 31 (44/142) | 0.091† |
Permanent hypothyroid (%) | 20 (3/15) | 2 (3/142) | 0.012† |
Recurrent disease (%) | 13 (2/15) | 14 (20/142) | >0.999† |